On the first day, Amgen detailed the rapid advancement of its KRAS inhibitor and Tempus unveiled an AI device to help oncologists deliver precision oncology.
The company aims to use the methylation technology from its multi-cancer screening assay to detect minimal residual disease in early-stage cancer patients.
Although a record number of new precision oncology drugs came to market, the pandemic further exposed access gaps that the field is focused on mitigating.
The drugmaker will work with McKesson's Ontada to gather real-world data insights on molecular testing and cancer treatment patterns and identify access gaps.
The company said data from the Phase II portion of the CodeBreak-100 study in KRAS-mutated lung cancer patients was positive and may be registrational.
